Tali Friedman-Korn1, Dan Meir Livovsky1, Nitsan Maharshak2,3, Nathaniel Aviv Cohen2,3, Kalman Paz1, Ariella Bar-Gil Shitrit1, Eran Goldin1, Benjamin Koslowsky4. 1. Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel. 2. Bacteriotherapy Clinic, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Tel Aviv, Israel. 3. The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 4. Digestive Diseases Institute, Shaare Zedek Medical Center, Jerusalem, Israel. binyaminkos@szmc.org.il.
Abstract
BACKGROUND: Fecal microbiota transplantation (FMT) is a new technique recently introduced to treat recurrent Clostridium difficile infection (CDI). Little is known about the efficacy and risks of FMT in elderly and ill patients. AIM: To investigate FMT efficacy in ill and elderly patients compared to conventional treatment. METHODS: The study comprised two groups of patients between 2012 and 2016 with recurrent CDI at two medical centers in Israel. The study group received FMT and the controls conventional therapy. The primary end points were CDI recurrence, length of hospitalization, and short-term survival. RESULTS: Thirty-four patients altogether, (21 females, mean age 82 years) participated, 11 received FMT and 23 controls. Demographics and clinical characteristics were similar between the two groups. Comorbidity indexes, i.e., Charlson index was high in both groups. In the FMT group, 10/11 (90%) patients showed clinical improvement 3 days after initiating treatment compared to 9/23 (39%) in the control group, p = 0.02. Survival at 2 months did not differ between the groups (FMT 54%, Control 50%, p = 0.816), but mean survival in the FMT group was higher than in the control (12 vs. 4 months, respectively, p = 0.015). Two significant adverse events from the FMT group included suspected aspirations, both occurring during gastroscopy route of administration. CONCLUSIONS: FMT is effective for elderly and very ill patients. Safety is a concern, but is rare even in patients with much comorbidity. Colonoscopy may be the preferred route of FMT infusion.
BACKGROUND: Fecal microbiota transplantation (FMT) is a new technique recently introduced to treat recurrent Clostridium difficileinfection (CDI). Little is known about the efficacy and risks of FMT in elderly and ill patients. AIM: To investigate FMT efficacy in ill and elderly patients compared to conventional treatment. METHODS: The study comprised two groups of patients between 2012 and 2016 with recurrent CDI at two medical centers in Israel. The study group received FMT and the controls conventional therapy. The primary end points were CDI recurrence, length of hospitalization, and short-term survival. RESULTS: Thirty-four patients altogether, (21 females, mean age 82 years) participated, 11 received FMT and 23 controls. Demographics and clinical characteristics were similar between the two groups. Comorbidity indexes, i.e., Charlson index was high in both groups. In the FMT group, 10/11 (90%) patients showed clinical improvement 3 days after initiating treatment compared to 9/23 (39%) in the control group, p = 0.02. Survival at 2 months did not differ between the groups (FMT 54%, Control 50%, p = 0.816), but mean survival in the FMT group was higher than in the control (12 vs. 4 months, respectively, p = 0.015). Two significant adverse events from the FMT group included suspected aspirations, both occurring during gastroscopy route of administration. CONCLUSIONS: FMT is effective for elderly and very ill patients. Safety is a concern, but is rare even in patients with much comorbidity. Colonoscopy may be the preferred route of FMT infusion.
Authors: Ju Young Chang; Dionysios A Antonopoulos; Apoorv Kalra; Adriano Tonelli; Walid T Khalife; Thomas M Schmidt; Vincent B Young Journal: J Infect Dis Date: 2008-02-01 Impact factor: 5.226
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: William M Tauxe; John P Haydek; Paulina A Rebolledo; Emma Neish; Kira L Newman; Angela Ward; Tanvi Dhere; Colleen S Kraft Journal: Therap Adv Gastroenterol Date: 2015-12-31 Impact factor: 4.409
Authors: Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann Journal: JAMA Date: 2014-11-05 Impact factor: 56.272
Authors: Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller Journal: N Engl J Med Date: 2013-01-16 Impact factor: 91.245
Authors: Wijnanda J Frenkel; Erika J Jongerius; Miranda J Mandjes-van Uitert; Barbara C van Munster; Sophia E de Rooij Journal: J Am Geriatr Soc Date: 2014-01-21 Impact factor: 5.562
Authors: Josbert J Keller; Rogier E Ooijevaar; Christian L Hvas; Elisabeth M Terveer; Simone C Lieberknecht; Christoph Högenauer; Perttu Arkkila; Harry Sokol; Oleksiy Gridnyev; Francis Mégraud; Patrizia K Kump; Radislav Nakov; Simon D Goldenberg; Reetta Satokari; Sergiy Tkatch; Maurizio Sanguinetti; Giovanni Cammarota; Andrey Dorofeev; Olena Gubska; Gianluca Laniro; Eero Mattila; Ramesh P Arasaradnam; Shiv K Sarin; Ajit Sood; Lorenza Putignani; Laurent Alric; Simon M D Baunwall; Juozas Kupcinskas; Alexander Link; Abraham G Goorhuis; Hein W Verspaget; Cyriel Ponsioen; Georgina L Hold; Herbert Tilg; Zain Kassam; Ed J Kuijper; Antonio Gasbarrini; Chris J J Mulder; Horace R T Williams; Maria J G T Vehreschild Journal: United European Gastroenterol J Date: 2021-03-09 Impact factor: 4.623